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money saved annually with the Sandimmun Neoral-based main-
tenance immunosuppression regimen was found to be about
776,000 roubles per transplant recipient per year. CONCLU-
SION: Sandimmun Neoral is the leading alternative for
immunosuppression following renal transplantation, i. e. it is
preferable from a clinicoeconomic perspective.
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OBJECTIVES: Standard medicinal care of patients with urge or
mixed urinary incontinence is muscarinic receptor antagonists.
Alternative forms of administration are available for these drugs.
The objective of this analysis was to compare the cost effective-
ness of the only available transdermal oxybutynin patch with
oral long-acting tolterodine tablets in the treatment of patients
with urge or mixed urinary incontinence in Sweden. METHODS:
The efﬁcacy of oxybutynin patches (3.9 mg/day), and tolterodine
tablets (4 mg/day) was compared in a 12 weeks randomized
clinical trial with 361 patients. The study demonstrated a com-
parable clinical efﬁcacy between the treatment alternatives in
number of daily incontinence episodes, average void volume and
QoL. A cost minimization analysis (CMA) was performed based
on this trial where direct medical costs related to drug treatments
and the costs of treating the major adverse events (AE)
(erythema, pruritus, rash, dry mouth, diarrhoea and constipa-
tion) were included. Resource utilization associated with the
treatment of the adverse events in Swedish clinical practice was
assessed by Swedish specialists in the ﬁeld. RESULTS: The CMA
shows that the total costs for 12 weeks tolterodine treatment is
1113.- SEK (~119.- €) per patient while the total costs for 12
weeks oxybutynin treatment is 1067.- SEK (~114.- €). The results
also demonstrate that the cost of treating AEs compose an insig-
niﬁcant fraction of the total treatment costs. This is due to the
low frequency of AEs requiring treatment, together with the low
costs for treating each AE. A number of sensitivity analyses
demonstrate the robustness of the results, including various sce-
narios for extrapolating the ﬁndings over 52 weeks. CONCLU-
SION: This CMA ﬁnds that oxybutynin patches (3.9 mg/day) is
a cost-effective treatment alternative to tolterodine tablets (4 mg/
day) for treating patients with urged or mixed urinary inconti-
nence in Sweden.
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OBJECTIVES: To assess clinical effectiveness and costs of MMF
or TAC use in immunosuppressive treatment from public payer’s
perspective in Poland. METHODS: Results of a SR of published
clinical trials conducted in December 2006 according to Polish
HTA Guidelines were used to assess effectiveness and safety for
immunosuppressive therapy schemes: TAC + AZA + GCS or
MMF + CsA + GCS. Weibull survival function was used to assess
the risk of acute kidney rejection, graftectomy, dialysis, retrans-
plantion (post-transplantation events) caused by used therapy.
Costs of treatment valid from public payer’s perspective were
taken into account. Pharmacotherapy, drug administration and
monitoring, patient monitoring, post-transplantation events
inﬂuenced the total treatment cost. Markov model was used to
assess costs of immunosuppressive therapies. Sensitivity analysis
was conducted according to range of costs of MMF or TAC
(+/-20%) available in Poland, MMF reimbursement categories
and discount rates for effects and costs in line with the Polish
HTA Guidelines (0% or 5%). All calculations were performed
for 2007 (1EUR = 3.8PLN). RESULTS: Indirect comparison
of immunosuppressive therapy schemes were taken into
account: TAC + AZA + GCS and MMF + CsA + GCS (CsA +
AZA + GCS as common comparator). Review of RCTs for these
therapies included in indirect comparison revealed no signiﬁcant
differences in their effectiveness and safety. TAC use was associ-
ated with signiﬁcantly higher costs from public payer’s perspec-
tive compared to MMF (difference: 97457PLN-135616PLN) per
therapy in accordance with assumed reimbursement category for
MMF (lump co-payment–50% co-payment). Sensitivity analysis
conﬁrmed that MMF’s scheme was cheaper compared to TAC’s
scheme from public payer’s perspective in Poland. CONCLU-
SION: MMF’s therapeutic scheme use in place of TAC’s scheme
lead to signiﬁcant savings for public payer in kidney transplant
immunosuppressive therapy in Poland.
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OBJECTIVES: The aim of our study was to assess the health
status and costs of patients with renal failure undergoing hae-
modialysis treatment in Hungary. METHODS: A questionnaire
survey was performed between November-December, year 2006
in the BBraun Dialysis Centre of Kistarcsa. All patients receiving
heamodialysis were invited to participate in the study. Demo-
graphic data, health care utilisation, informal care, transporta-
tion and other disease related expenses were surveyed. A generic
health status measure, the EQ-5D (range -0.6–1) was applied.
Mobility was measured by the Timed Up and Go Test
(normal < 20 sec). Costing was performed using human capital
approach method, productivity loss was based on average gross
wage (629Euro/month). RESULTS: Seventy-one patients (35
women, 36 men) were involved, mean age 62.3(15.0) years,
duration of haemodialysis was mean 3.9(4.2) years. 34 (47.8%)
patients were retired as many as on maintenance of disabled,
1-1-1 was on permanent sick-leave, unemployed or student.
Patients’ residence was mean 18.6(14.2) km from the dialysis
centre, 23(32.4%) had a car in their household, 2(2.8%) drived
on his own and 4(5.6%) were taken by a relative regularly,
57(80.3%) used the centres’ transportation network. 4(5.6%)
came by ambulance as much as travelled by bus or train.
9(12.7%) patients were living alone, 24(33.8%) with spouse,
37(52.1%) with other relatives, 1 in a nursing home, 28(39.4%)
received regular informal care mean 35.8(25.5) hours/week.
EQ-5D score was mean 0.635(0.3) and the score was signiﬁ-
cantly lower (p < 0.01) in all age-groups than in the Hungarian
population. The Up and Go Test was mean 19.89(17.09) sec.
Mean cost was 21 572 Euro/patient/year, direct medical costs
85.4%, direct non-medical costs 5.8%, indirect costs 8.8%.
CONCLUSION: Health status loss is signiﬁcant in chronic renal
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